Can abruptly stopping lorazepam or zolpidem cause withdrawal-related confusion or delirium, especially in older adults?

Abrupt stopping of lorazepam or zolpidem can remove ongoing GABA-A receptor potentiation as drug levels fall and, in a physically dependent person, precipitate a hyperexcitable withdrawal state. For a 77-year-old, acute confusion after a medication change warrants particular concern.

Clinical evidence and safety

• Lorazepam: Rapid reduction or cessation is FDA-recognized to cause potentially life-threatening withdrawal. Severe manifestations include confusion, hallucinations, delirium, seizures, and autonomic instability, especially after regular, prolonged, or high-dose exposure.
• Zolpidem: Withdrawal delirium, agitation, psychosis, and seizures are documented most clearly in reports involving prolonged or supratherapeutic use. Standard-dose discontinuation often causes little more than rebound insomnia, but risk rises with dependence-producing exposure.
• Timing can be rapid: lorazepam withdrawal may begin within roughly 1–3 days (sometimes about a day), while zolpidem rebound or withdrawal symptoms may begin the first night to 24–48 hours after stopping.
• Delirium has been observed after abrupt benzodiazepine cessation (e.g., 2/70 participants in one tapering-study summary, both after abrupt cessation), though age-specific incidence is unavailable.

Mechanism

• Both agents are positive allosteric modulators of GABA-A receptors. Chronic exposure can produce impaired GABAergic coupling, altered receptor-subunit expression, and compensatory glutamatergic/excitatory activity. Sudden removal of drug-supported inhibition can therefore cause agitation, insomnia, perceptual symptoms, autonomic instability, delirium, or seizures.

Older-age implications

• Adults ≥65 have greater baseline vulnerability to medication-related cognitive impairment and delirium, with age-related pharmacologic sensitivity and slower metabolism supporting heightened clinical concern. Direct evidence quantifying excess withdrawal-delirium risk by age is not available.

Bottom line

• Abrupt discontinuation is clinically risky, particularly with established dependence. New fluctuating confusion, severe agitation, hallucinations, autonomic symptoms, or seizures after stopping warrants urgent medical assessment; individualized, supervised gradual tapering is the risk-reduction approach.